We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

c-Kit

c-Kit inhibitors block the stem cell factor (SCF) receptor, a tyrosine kinase of mast cells and blood progenitors. Human c-kit was cloned in 1987 as a cell surface receptor tyrosine kinase whose ligand was not yet known. In 1998 gain-of-function c-kit mutations were reported in gastrointestinal stromal tumors, making the receptor a model oncogenic kinase. Most compounds here have broader profiles, and imatinib and imatinib mesylate also act on the platelet-derived growth factor receptor (PDGFR) and Abelson kinase (Abl). Dasatinib inhibits Src family kinases and the D816V c-Kit mutant. Pexidartinib targets c-Kit together with colony-stimulating factor 1 receptor (CSF-1R) and FMS-like tyrosine kinase 3 (FLT3). Pazopanib HCl inhibits c-Kit together with vascular endothelial growth factor receptors (VEGFRs).

1 Item

  • c-Kit Receptor modulator-1
    Cat. No.
    A34593
    CAS No.
    932401-20-2

    c-Kit Receptor modulator-1

    c-Kit Receptor modulator-1 is a selective modulator of the c-Kit receptor, primarily involved in cell signaling pathways associated with hematopoiesis and mast cell function. This compound exhibits potent activity against malignancies such as canine mastocytoma, human gastrointestinal stromal tumors, and small cell lung cancer. It is a valuable tool for research focused on tumor biology and therapeutic interventions targeting c-Kit signaling pathways.

    View Details

    Out of stock

    All 3 sizes

1 Item

Added to your cart

View Cart Checkout

    Loading...